Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biothera has taken over Antisoma's anticancer monoclonal antibody, AS1402, which target aberrant form of the cell-surface protein in MUC1 that is expressed in many types of cancer.
Subscribe to our email newsletter
In future, Biothera is planning to conduct trials with the combination therapy of Imprime PGG and AS1402.
Imprime PGG is a new immunotherapy that works synergistically with anti-tumor monoclonal antibodies.
Biothera Pharma president Dan Conners said they believe the combination of Imprime PGG and AS1402 could create a potent therapy to treat a wide range of cancer.
Antisoma Business Development vice president Nicholas Adams said this deal gives Biothera the opportunity to pursue an interesting new approach with AS1402 while at the same time realising value for Antisoma.